Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Skaltsa

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)O Ghatnekar, K Nørgaard, K Skaltsa
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Decision Drivers For Brazil: An Analysis of Conitec RecommendationsJ Kreeftmeijer, K Skaltsa, D Palazzolo
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Mapping Fact-P To EQ-5D In Metastatic Castration-Resistant Prostate Cancer (MCRPC): Performance Of A Previously Developed Algorithm When Applied On A Sample With A Different Disease StageC Ivanescu, L Longworth, K Skaltsa, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Do health technology agencies accept methods for dealing with treatment switching?J Maervoet, K Skaltsa, C Ivanescu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Immature Survival Data From Early Trial Termination - Theory and Hta PracticeA Pruefert, K Skaltsa, J Maervoet, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
An Archetype For Classification and Comparison of Hta Activities in Latin AmericaK Skaltsa, N Allen, Engen A Van, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|June 15, 2012
PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancerJ Duch, D Fuster, M Muñoz, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)O Ghatnekar, K Nørgaard, K Skaltsa
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Decision Drivers For Brazil: An Analysis of Conitec RecommendationsJ Kreeftmeijer, K Skaltsa, D Palazzolo
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Mapping Fact-P To EQ-5D In Metastatic Castration-Resistant Prostate Cancer (MCRPC): Performance Of A Previously Developed Algorithm When Applied On A Sample With A Different Disease StageC Ivanescu, L Longworth, K Skaltsa, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Do health technology agencies accept methods for dealing with treatment switching?J Maervoet, K Skaltsa, C Ivanescu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Immature Survival Data From Early Trial Termination - Theory and Hta PracticeA Pruefert, K Skaltsa, J Maervoet, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
An Archetype For Classification and Comparison of Hta Activities in Latin AmericaK Skaltsa, N Allen, Engen A Van, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|June 15, 2012
PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancerJ Duch, D Fuster, M Muñoz, et al.
Pageof 1